Zoetis rises after beating quarterly estimates
12/02/2026 12:33
** Shares of animal healthcare company Zoetis ZTS.N rise 4.37% to $134.68 premarket ** Co expects 2026 adjusted EPS of $7.00 to $7.10, the midpoint of which is above analysts’ estimates of $6.80 - data compiled by LSEG ** Forecasts 2026 revenue of $9.825 billion to $10.025 billion, the midpoint of which is above Street view of $9.914 billion ** Reports Q4 adjusted profit per share of $1.48 vs. estimates of $1.40 - LSEG data ** Shares fell ~23% in 2025 (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))
Recent news on Zoetis
See all newsBrief: Zoetis Receives FDA Approval For Convenia® Rtu For Dogs (Cefovecin Injectable Suspension), Helping More Medium And Large Dogs Access Single-Injection Treatment
Brief: FDA Approves Ready-To-Use Cefovecin Injectable For Treatment Of Certain Skin Infections In Dogs
U.S. RESEARCH ROUNDUP-Masco, Sherwin-Williams, Vulcan Materials
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
Brief: FDA Issues Emergency Use Authorization For Simparica Trio To Treat New World Screwworm In Dogs, Puppies